ATE323766T1 - Glykosylierte leptinzusammensetzungen und zugehörige verfahren - Google Patents
Glykosylierte leptinzusammensetzungen und zugehörige verfahrenInfo
- Publication number
- ATE323766T1 ATE323766T1 AT00911784T AT00911784T ATE323766T1 AT E323766 T1 ATE323766 T1 AT E323766T1 AT 00911784 T AT00911784 T AT 00911784T AT 00911784 T AT00911784 T AT 00911784T AT E323766 T1 ATE323766 T1 AT E323766T1
- Authority
- AT
- Austria
- Prior art keywords
- proteins
- glycosylated
- compositions
- glycosylated leptin
- leptin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24967599A | 1999-02-12 | 1999-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE323766T1 true ATE323766T1 (de) | 2006-05-15 |
Family
ID=22944511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00911784T ATE323766T1 (de) | 1999-02-12 | 2000-02-11 | Glykosylierte leptinzusammensetzungen und zugehörige verfahren |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1151102B1 (de) |
JP (1) | JP4841037B2 (de) |
AT (1) | ATE323766T1 (de) |
AU (1) | AU781460B2 (de) |
CA (1) | CA2359840C (de) |
CY (1) | CY1107470T1 (de) |
DE (1) | DE60027409T2 (de) |
DK (1) | DK1151102T3 (de) |
ES (1) | ES2257287T3 (de) |
PT (1) | PT1151102E (de) |
WO (1) | WO2000047741A1 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
EP1420812A1 (de) * | 2001-08-29 | 2004-05-26 | The University of Buckingham | Verwendung von leptin für kinder mit niedrigem geburtsgewicht zur vorbeugung von fettleibigkeit |
PL214862B1 (pl) * | 2001-10-22 | 2013-09-30 | Amgen | Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny |
US7094579B2 (en) | 2002-02-13 | 2006-08-22 | Xoma Technology Ltd. | Eukaryotic signal sequences for prokaryotic expression |
EP1587923B1 (de) | 2003-01-22 | 2011-08-24 | Duke University | Verbesserte konstrukte zur expression lysosomaler polypeptide |
WO2005030963A1 (en) | 2003-09-26 | 2005-04-07 | Applied Research Systems Ars Holding N.V. | Leader sequences for use in production of proteins |
HUE026826T2 (en) * | 2004-10-29 | 2016-07-28 | Ratiopharm Gmbh | Modeling and glycopegylation of fibroblast growth factor (FGF) |
US8716220B2 (en) | 2005-09-07 | 2014-05-06 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta |
WO2008067599A1 (en) * | 2006-12-04 | 2008-06-12 | Apollo Life Sciences Limited | Isolated leptin and adiponectin molecules and chimeric molecules thereof |
US9493499B2 (en) | 2007-06-12 | 2016-11-15 | Novo Nordisk A/S | Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography |
JP2009126856A (ja) * | 2007-11-28 | 2009-06-11 | Fancl Corp | 血中中性脂肪上昇抑制剤 |
CA2725143A1 (en) | 2008-05-21 | 2009-11-26 | Neurotez, Inc. | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
WO2009149379A2 (en) | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
DK3241558T3 (da) | 2010-09-28 | 2021-04-26 | Aegerion Pharmaceuticals Inc | Højopløselige leptiner |
MX349035B (es) | 2012-05-17 | 2017-07-07 | Extend Biosciences Inc | Portadores para el suministro mejorado de farmaco. |
EP2900230B1 (de) | 2012-09-27 | 2018-08-15 | The Children's Medical Center Corporation | Substanzen zur behandlung von obesitas und methoden zu deren verwendung |
AU2014354831B2 (en) | 2013-11-26 | 2017-10-26 | The Children's Medical Center Corporation | Compounds for the treatment of obesity and methods of use thereof |
US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
JP6946182B2 (ja) | 2014-10-22 | 2021-10-06 | エクステンド バイオサイエンシズ インコーポレーテッドExtend Biosciences, Inc | 治療用ビタミンdコンジュゲート |
CN110267674A (zh) * | 2016-07-08 | 2019-09-20 | 奥美药业有限公司 | 包含瘦素的融合蛋白及其生产和使用方法 |
BR112019004715A2 (pt) | 2016-09-12 | 2019-07-16 | Aegerion Pharmaceuticals Inc | métodos para detectar anticorpos neutralizantes anti-leptina |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5326700A (en) * | 1990-11-06 | 1994-07-05 | Eli Lilly And Company | DNA sequences encoding t-PA derivatives with cleavable sites |
ZA946122B (en) * | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
WO1996023815A1 (en) * | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Ob gene product antibodies |
EP1285664B1 (de) * | 1995-11-22 | 2010-01-20 | Amgen Inc. | Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen |
AU1406497A (en) * | 1995-12-06 | 1997-06-27 | Schering Corporation | Mutational variants of mammalian ob gene proteins |
JPH09176198A (ja) * | 1995-12-28 | 1997-07-08 | Kikkoman Corp | 抗肥満タンパク質モノクローナル抗体及びハイブリドーマ |
US5831017A (en) * | 1996-01-25 | 1998-11-03 | Eli Lilly And Company | Obesity protein analog compounds and formulations thereof |
EP0827750A3 (de) * | 1996-08-23 | 2002-11-20 | Eli Lilly And Company | Formulierungen des Obesitäts-Proteins |
WO1999023115A1 (en) * | 1997-10-31 | 1999-05-14 | Eli Lilly And Company | Glycosylated obesity protein analogs |
DE69921486T2 (de) * | 1998-08-10 | 2006-02-02 | Amgen Inc., Thousand Oaks | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren |
US6420339B1 (en) * | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
-
2000
- 2000-02-11 AT AT00911784T patent/ATE323766T1/de active
- 2000-02-11 WO PCT/US2000/003652 patent/WO2000047741A1/en active IP Right Grant
- 2000-02-11 ES ES00911784T patent/ES2257287T3/es not_active Expired - Lifetime
- 2000-02-11 PT PT00911784T patent/PT1151102E/pt unknown
- 2000-02-11 AU AU33623/00A patent/AU781460B2/en not_active Ceased
- 2000-02-11 JP JP2000598639A patent/JP4841037B2/ja not_active Expired - Fee Related
- 2000-02-11 CA CA2359840A patent/CA2359840C/en not_active Expired - Fee Related
- 2000-02-11 DK DK00911784T patent/DK1151102T3/da active
- 2000-02-11 DE DE60027409T patent/DE60027409T2/de not_active Expired - Lifetime
- 2000-02-11 EP EP00911784A patent/EP1151102B1/de not_active Expired - Lifetime
-
2006
- 2006-07-07 CY CY20061100939T patent/CY1107470T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2359840A1 (en) | 2000-08-17 |
ES2257287T3 (es) | 2006-08-01 |
DK1151102T3 (da) | 2006-05-29 |
JP4841037B2 (ja) | 2011-12-21 |
DE60027409D1 (de) | 2006-05-24 |
JP2002536018A (ja) | 2002-10-29 |
CY1107470T1 (el) | 2012-12-19 |
CA2359840C (en) | 2012-10-23 |
AU3362300A (en) | 2000-08-29 |
AU781460B2 (en) | 2005-05-26 |
EP1151102B1 (de) | 2006-04-19 |
DE60027409T2 (de) | 2007-04-12 |
WO2000047741A1 (en) | 2000-08-17 |
PT1151102E (pt) | 2006-07-31 |
EP1151102A1 (de) | 2001-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107470T1 (el) | Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι | |
AU2001254624A1 (en) | Human coagulation factor vii variants | |
BRPI0410164A (pt) | composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano | |
CY1112655T1 (el) | Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις | |
EP1484339A3 (de) | Kallikreinhemmende "Kunitz-Domäne"Proteine dafür kodierende Nukleinsäure | |
YU48703A (sh) | Novi interferonu beta-slični molekuli | |
HUP0001153A2 (hu) | Kémiailag módosított polipeptidek, eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
DK1005540T3 (da) | IKK-beta-proteiner, nukleinsyrer og fremgangsmåder | |
WO2003059934A3 (en) | Albumin fusion proteins | |
AU2003215524A1 (en) | Pharmaceutical compositions comprising mannose binding lectin | |
HUP0103758A2 (hu) | Neurotróf faktorok | |
CY1111431T1 (el) | Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων | |
WO1995025171A3 (de) | Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung | |
WO2003033658A3 (en) | Neutrokine-alpha and neutrokine-alpha splice variant | |
HUP0500637A2 (hu) | Neublasztin polimer konjugátumai és alkalmazási eljárásai | |
IL81221A0 (en) | Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them | |
DK0877803T3 (da) | OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder | |
EP0369816A3 (de) | Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper | |
FI964186A0 (fi) | Ei-liittävät gp350/220-variantit | |
DE69529750D1 (de) | Verbesserungen in der herstellung von proteinen in wirtszellen | |
BR0211991A (pt) | HormÈnio do crescimento humano modificado | |
WO2002007514A3 (en) | Glycosylated vegf-b and method for increasing the amount of soluble vegf-b | |
ATE230027T1 (de) | Menschliche dnase i varianten | |
UA81601C2 (ru) | Полипептид фактора vii и его применения для лечения случаев кровотечения или усиление нормальной системы кровоостановки | |
WO2002102849A3 (en) | Bcmp-101, a cancer associated protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1151102 Country of ref document: EP |